p53-oriented cancer therapies: Current progress

Annals of Oncology

Volumn 10, Issue 2, 1999, Pages 139-150

  Gallagher, W M ^a   Brown, R ^b  

^a SANOFI   (France)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Apoptosis; Chemotherapy; Clinical trials; Gene therapy; P53

Indexed keywords

PROTEIN P53;

APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CYCLE; DNA DAMAGE; GENE MUTATION; GENE TARGETING; GENE THERAPY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL RATE;

EID: 0033053944     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008368500557     Document Type: Review

References (144)

1. Ko LJ, Prives C. p53: Puzzles and paradigm. Genes Dev 1996; 10: 1054-72.
2. Hansen R, Oren M. p53: From inductive signal to cellular effect. Curr Opin Genet Dev 1997; 7: 46-51.
3. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91.
4. Zhan Q, Fan S, Smith ML et al. Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. DNA Cell Biol 1996; 15: 805-15.
5. Nitta M, Okamura H, Aizawa S, Yamaizumi M. Heat shock induces transient p53-dependent cell cycle arrest at G1/S. Oncogene 1997; 15: 561-8.
6. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
7. Wang XW, Harris CC. TP53 tumour suppressor gene: Clues to molecular carcinogenesis and cancer therapy. Cancer Surveys 1996; 28: 169-96.
8. Bates S, Vousden KH. p53 In signalling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996; 6: 12-9.
9. Gotz C, Montenarh M. p53: DNA damage. DNA repair and apoptosis. Rev Physiol Biochem Pharmacol 1996; 127: 65-95.
10. Gottlieb TM, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287: 77-102.
11. Wahl GM, Linke SP, Paulson TG, Huang L. Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surveys 1997; 29: 183-219.
12. Kastan MB, Onyckwere O, Sidransky D et al. Participation of p53 19; protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
13. Di Leonardo A, Linke SP, Clarkin KC, Wahl GM. DNA damage triggers a prolonged p53-depondent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994; 8: 2540-51.
14. El-Deiry WS, Harper JW, O'Connor PM et al. WAF-1/CIP-1 is induced in p53-mediated G1 arrest and apoplosis. Cancer Res 1994; 54: 1169-74.
15. Xiong Y, Zhang H, Beach D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572-83.
16. Dulic V, Kaufmann WK, Wilson SJ et al. p53-Dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994; 76: 1013-23.
17. Slebos RJC, Lee MH, Flunkett BS et al. p53-Dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 1994; 91: 5320-4.
18. Brugarolas J, Chandrasekaran C, Gordon JI et al. Radiation-induced cell cycle arrest comprimised by p21 deficiency. Nature 1995; 377: 552-7.
19. Macleod KF, Sherry N, Hannon G et al. p53 Dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dev 1995; 9: 935-44.
20. Vikhanskaya F, Erba E, D'Incalci M, Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994; 22: 1012-7.
21. Agarwal ML, Agarwal A, Taylor WL, Stark GR. p53 Controls both the G2/M and the G1 cell cycle checkpoint and mediates growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995; 92: 8493-7.
22. Stewart N, Hicks GG, Paraskevas F, Mowat M. Evidence for a second-cell cycle block at G2/M by p53. Oncogene 1995; 10: 109-15.
23. Cross SM, Sanchez CA, Morgan CA et al. A p53-dependent mouse spindle checkpoint. Science 1995; 267: 1353-6.
24. Oren M. Relationship of p53 to the control of apoptotic cell death. Sem Cancer Biol 1994; 5: 221-7.
25. Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-52.
26. Lowe SW, Scmitt EM, Osborne BA, Jacks T. p53 Is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
27. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
28. Lowe SW, Bodis S, McClatchey A et al. p53 Status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10.
29. Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-9.
30. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-5.
31. White E. Life, death and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15.
32. Liebermann D, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-Dependent and independent pathways. Oncogene 1995; 11: 199-210.
33. Jones NA, Turner J, McIlwrath AJ et al. Cisplatin and paclitaxel induced apoptosis of human ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998; 53: 819-26.
34. Caelles C, Helmberg A, Karin M. p53-Dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 1994; 370: 220-3.
35. Wagner AJ, Kokontis JM, Hay N. Myc-mediated apoptosis requires wild type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 wafl/cipl. Genes Dev 1994; 8: 2817-30.
36. Wang XW, Vermeulen W, Coursen JD et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996; 10: 1219-32.
37. Hinds PW, Finlay CA, Quartin RS et al. Mutant p53 DNA clones from human colon carcinomas co-operate with ras in transforming primary rat-cells a comparison of the hotspot mutant phenotypes. Cell Growth Differential 1990; 1: 571-80.
38. Milner J, Medcalf EA. Cotraslation of the activated mutant p53 with wild type drives the wild-type protein into the mutant conformation. Cell 1991; 65: 765-74.
39. Hann BC, Lane DP. The dominating effect of mutant p53. Nature Genet 1995; 9: 221-2.
40. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of Activity of the Promoter of the Human MDR1 Gene by Ras and p53. Science 1992; 255: 459-62.
41. Deb S, Jackson T, Subler MA, Martin DW. Modulation of cellular and viral promoters by mutant human p53 protein found in tumour cells. J Virol 1992; 66: 6164-70.
42. Chen Y, Chen P, Lee W. Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol 1994; 14: 6764-72.
43. Iwabuchi K, Bartel PL, Li B et al. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 1994; 91: 6098-102.
44. Oliner JD, Pietenpol JA, Thiagalingam S et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-60.
45. Meltzer PS. MDM2 and p53: A question of balance. J Natl Cancer Inst 1994; 86: 1265-6.
46. Chen J, Wu X, Lin J, Levine AJ. Mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumour suppressor protein. Mol Cell Biol 1996; 16: 2445-52.
47. Lane DP, Hall PA, MDM2-arbiter of p53's destruction. Trends Biochem Sci 1997; 22: 372-4.
48. Moll UM, LaQuaglia M, Benard J, Riou G, Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumours. Proc Natl Acad Sci USA 1995; 92: 4407-11.
49. Lechner MS, Mack DH, Finicle AB et al. Human papillomavirus E6 protein binds p53 in vivo and abrogates p53-mediated repression of transcription. EMBO J 1992; 11: 3045-52.
50. Wang XW, Forrester K, Yeh H et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91: 2230-4.
51. Thomas M, Massimi P, Banks L. HPV-18 E6 inhibits DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene 1996; 13: 471-80.
52. Thomas M, Matlashewski G, Pim D, Banks L. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene 1996; 13: 265-73.
53. Meek DW. Post-translational modification of p53 and the integration of stress signals. Pathol Biol 1997; 45: 777-908.
54. Sakaguchi K, Herrera JE, Saito S et al. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998; 12: 2831-41.
55. Siliciano JD, Canman CE, Taya Y et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-81.
56. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumour-suppressor gene in clinical oncology. J Clin Oncol 1995; 13: 1009-22.
57. Sidransky D, Hollstein M, Clinical implications of the p53 gene. Ann Rev Med 1996; 47: 285-301.
58. Ruley HE. p53 And response to chemotherapy and radiotherapy. In De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia: Lippincott Raven Publishers 1996; 37-56.
59. Lowe SW. Cancer therpay and p53. Curr Opin Oncol 1995; 7: 547-53.
60. Bergh J, Norberg T, Sjorgen S et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvunct systemic therapy and rediotherapy. Nature Med 1995; 1: 1029-34.
61. Fan S, Smith ML, Rivet DJ et al. Disruption of p53 function sensitises breast cancer MCF-7 cells to cisplalin and pentoxifylline. Cancer Res 1995; 55: 1649-54.
62. Wu GS, El-Deiry WS. Apoptotic death of tumour cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 1996; 2: 623-33.
63. Waldman T, Zhang YG, Dillehay L et al. Cell-cycle arrest versus cell death in cancer therapy. Nature Med 1997; 3: 1034-6.
64. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989; 57: 1083-93.
65. Goyette MC, Cho K, Fasching CL et al. Progression of colorectal-cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 1992; 12: 1387-95.
66. Takahashi T, Carbone D, Nau MM et al. Wild-type but not mutant p53 suppresses the growth of human lung-cancer cells bearing multiple genetic lesions. Cancer Res 1992; 52: 2340-3.
67. Nielsen LL, Maneval DC. p53 Tumour suppressor gene therapy for cancer. Cancer Gene Ther 1997; 4: 129-38.
68. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
69. Cai DW, Mukhopadhyay T, Liu YJ et al. Stable expression of the wild-type p53 gene in human lung-cancer cells after retrovirus-mediated gene-transfer. Human Gene Ther 1993; 4: 617-24.
70. Fujiwara T, Grimm EA. Mukhopadhyay T et al. A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993; 53: 4129-33.
71. Fujiwara T, Cai DW, Georges RN et al. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 1994; 86: 1458-62.
72. Roth JA. Modification of tumor suppressor gene expression in non-small-cell lung cancer (nsclc) with a retroviral vector expressing wildtype (normal) p53. Human Gene Ther 1996; 7: 861-74.
73. Lesoonwood LA, Kim WH, Kleinman HK et al. Systemic genetherapy with p53 reduces growth and metastases of a malignant human breast cancer in nude-mice. Human Gene Ther 1995; 6: 395-405.
74. Nielsen LL, Dell J, Maxwell E et al. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther 1997; 4: 129-38.
75. Sandig V, Brand K, Herwig S et al. Adenovirally transferred p6(ink4/cdkn2) and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 1997; 3: 313-9.
76. Meng RD, Shih H, Prabhu NS et al. Bypass of abnormal mdm2 inhibition of p53-dependent growth suppression. Clin Cancer Res 1998; 4: 251-9.
77. McKie EA, MacLean AR, Lewis AD et al. Selective in vitro replication of herpes simplex virus type 1 (hsv-1) icp34.5 null mutants in primary human cns tumours - evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-52.
78. Howard MK, Kershaw T, Gibb B et al. High efficiency gene-transfer to the central nervous system of rodents and primates using herpes virus vectors lacking functional icp27 and icp34.5. Gene Ther 1998; 5: 1137-47.
79. Phelan A, Elliott G, Ohare P. Intercellular delivery of functional p53 by the herpesvirus protein vp22. Nature Biotech 1998; 16: 440-3.
80. Wolff JA, Malone RW, Williams P et al. Direct gene-transfer into mouse muscle in vivo. Science 1990; 247: 1465-8.
81. Vile RG, Hart IR. In vitro and in vivo targeting of gene-expression to melanoma-cells. Cancer Res 1993; 53: 962-7.
82. Habib NA, Ding SF, ElMasry R et al. Preliminary report: The short-term effects of direct p53 dna injection in primary hepatocellular carcinomas. Cancer Detect Prevent 1996; 20: 103-7.
83. Fricker J. Hepatocellular carcinoma and p53 gene therapy. Mol Med Today 1996; 2: 361.
84. Habib NA. Gene therapy for liver tumours. Cancer Gene Ther 1997; 4: 329-30.
85. Farhood H, Gao X, Son K et al. Cationic liposomes for direct gene-transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994; 716: 23-35.
86. Hsiao M, Tse V, Carmel J et al. Intracavitary liposome-mediated p53 gene transfer into glioblastoma with endogenous wild-type p53 in vivo results in tumor suppression and long-term survival Biochem Biophys Res Communicat 1997; 233: 359-64.
87. Xu M, Kumar D, Srinivas S et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Human Gene Ther 1997; 8: 177-85.
88. Xu L, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitisation of squamous cell carcinoma of the head and neck to radiation in vitro. Human Gene Ther 1997; 8: 467-75.
89. Zou Y, Zong G, Ling YH et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer Inst 1998; 90: 1130-7.
90. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-4.
91. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995; 55: 6161-5.
92. Bouvet M, Ellis LM, Nishizaki M et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288-92.
93. Holmgren L, Jackson G, Arbiser J. p53 Induces angiogenesis-restricted dormancy in a mouse fibrosarcoma. Oncogene 1998; 17: 819-24.
94. Riccioni T, Cirielli C, Wang X et al. Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. Gene Ther 1998; 5: 747-54.
95. Kieser A, Welch HA, Brandner G et al. Mutant p53 potentiates protein-kinase-c induction of vascular endothelial growth-factor expression. Oncogene 1994; 9: 963-9.
96. Wicczorek AM, Waterman JLF, Waterman MJF, Halazonetis TD. Structure-based rescue of common tumor-derived p53 mutants. Nature Med 1996; 2: 1143-6.
97. Brachmann RK, Yu K, Eby Y et al. Genetic selection of intragenic suppressor mutations that reverse the effects of common p53 cancer mutations. EMBO J 1998; 17: 1847-59.
98. Beaudry GA, Bertelsen AH, Sherman MI. Therapeutic targeting of the p53 tumour suppressor gene. Curr Opin Biotech 1996; 7: 592-600.
99. Harris CC. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
100. Zhang W, Guo XY, Hu GY et al. A temperature-sensitive mutant of human p53. EMBO J 1994; 13: 2535-44.
101. Abarzua P, LoSardo JE, Gubler ML, Neri A. Microinjection of monoclonal antibody PAb21 into human SW480 colorectal carcinoma cells restores the transcriptional activation function to mutant p53. Cancer Res 1995; 55: 3490-4.
102. Selivanova G, Iotsova V, Okan I et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 c-terminal domain. Nature Med 1997; 3: 632-8.
103. Blagosklonny MV, Toretsky J, Neckers L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene 1995; 11: 933-9.
104. Whitesell L, Sutphin PD, Pulcini EJ et al. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998; 18: 1517-24.
105. Dasgupta G, Momand J, Geldanamycin prevents nuclear translocation of mutant p53. Experiment Cell Res 1997; 237: 29-37.
106. Scanlon KJ, Ohta Y, Ishida H et al. Oligonucleotide-mediated modulation of mammalian gene-expression. Faseb J 1995; 9: 1288-96.
107. Kussie PH, Gorina S, Marechal V et al. Structure of the mdm2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274: 948-53.
108. Bottger A, Bottger V, Sparks A et al. Design of a synthetic mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7: 860-9.
109. Waterman MJF, Waterman JLF, Halazonetis TD. Engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. Cancer Res 1996; 56: 158-63.
110. Conseiller E, Debussche L, Landais D et al. Ctsl: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. J Clin Invest 1998; 101: 120-7.
111. Prabhu NS, Somasundaram K, Satyamoorthy K et al. p73β, unlike p53, suppresses growth and induces apoptosis of human papillomavirus e6-expressing cancer cells. Int J Oncol 1998; 13: 5-9.
112. Oconnor PM, Jackman J, Bae I et al. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.
113. Delia D, Mizutani S, Lamorte G et al. p53 Activity and chemotherapy. Nature Med 1996; 2: 724-5.
114. Vasey PA, Jones NA, Jenkins S et al. Cispaltin, camptothecin and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996; 50: 1536-40.
115. Debernardis D, Sire EG, DeFeudis P et al. p53 Status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997; 57: 870-4.
116. Fan S, Cherney B, Reinhold W et al. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after Taxol or vincristine treatment. Clin Cancer Res 1998; 4: 1047-54.
117. Wahl AF, Donaldson KL, Fairchild C et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 1996; 2: 72-9.
118. Brown R. p53: A target for new anticancer drugs or a target for old drugs? Ann Oncol 1993; 4: 623-9.
119. Cai DW, Mukhopadhyay T, Roth JA. Suppression of lung-cancer cell-growth by ribozyme-mediated modification of p53 pre-messenger-rna. Cancer Gene Ther 1995; 2: 199-205.
120. Bayever E, Haines KM, Iversen PL et al. Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide-sequences. Leuk Lymph 1994; 12: 223-31.
121. Janicek MF, Sevin BU, Nguyen HN, Averette HE. Combination anti-gene therapy targeting c-myc and p53 in ovarian-cancer cell-lines. Gynecol Oncol 1995; 59: 87-92.
122. Bishop MR, Iversen PL, Bayever E et al. Phase I trial of an antisense oligonucleotide o1(1)p53 in hematologic malignancies, J Clin Oncol 1996; 14: 1320-6.
123. Skilling JS, Squatrito RC, Connor JP et al. p53 Gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996; 60: 72-80.
124. Bishop MR, Jackson JD, Tarantolo SR et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide o1(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother 1997; 6: 441-6.
125. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71: 429-37.
126. Imamura J, Miyoshi I, Koeffler HP, p53 In hematologic malignancies. Blood 1994; 84: 2412-21.
127. Soussi T. The humoral response to the tumor-suppressor gene-product p53 in human cancer: Implications for diagnosis and therapy, Immunol Today 1996; 17: 354-6.
128. Chen HL, Carbone DP. p53 As a target for anti-cancer immunotherapy. Mol Med Today 1997; 3: 160-7.
129. Ciernik IF, Berzofsky J, Carbone DP. Mutant oncopeptide immunization induces ctl specifically lysing tumor-cells endogenously expressing the corresponding intact mutant p53. Hybridoma 1995; 14: 139-42.
130. Wiedenfeld EA, Fernandezvina M, Berzofsky JA, Carbone DP. Evidence for selection against human lung cancers bearing p53 missense mutations which occur within the hla a-asterisk-0201 peptide consensus motif. Cancer Res 1994; 54: 1175-7.
131. Mayordomo JI. Loftus DJ, Sakamoto H et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183: 1357-65.
132. Vierboom MPM, Nijman HW, Offringa R et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997; 186: 695-704.
133. Bertholet S, Iggo R, Corradin G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 1997; 27: 798-801.
134. Roth J, Dittmer D, Rea D et al. p53 As a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protects mice against lethal tumour cell damage. Proc Natl Acad Sci USA 1997; 93: 4781-6.
135. Ruiz PJ, Wolkowicz R, Waisman A et al. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Med 1998; 4: 710-2.
136. DaCosta LT, Jen J, He TC et al. Converting cancer genes into killer genes. Proc Natl Acad Sci USA 1996; 93: 4192-6.
137. Bischoff JR, Kirn DH, Williams A et al. An adenovirus mutant that replicates selectively in p53-deficient human tumour cells. Science 1996; 274: 373-6.
138. Heise C, Sampson-Johannes A, Williams A et al. Onyx-015, an E1B gene attenuated adenovirus, causes tumour-specific cytolysis and antitumoural efficacy that can be augmented by standard chemotherapeutic agents. Nature Med 1997; 3: 639-45.
139. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early 1b-protein. Nature 1992; 357: 82-5.
140. Ridgway PJ, Hall AR, Myers CJ, Braithwaite AW. p53/E1b58kDa complex regulates adenovirus replication. Virology 1997; 237: 404-13.
141. Goodrum FD, Ornelles DA. The early region 1B 55-kilodalton oncoprotein of adenovirus relieves growth restrictions imposed on viral replication by the cell cycle. J Virol 1997; 71: 546-61.
142. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-Dependent cell death apoptosis is required for a productive adenovirus infection. Nature Med 1998; 4: 1068-72.
143. Lane DP. Killing tumour cells with viruses-a question of specificity. Nature Med 1998; 4: 1012-3.
144. Freytag SO, Rogulski KR, Paielli DL et al. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Human Gene Ther 1998; 9: 1323-33.